This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
PA.3 was a randomized, parallel-group, double-blind phase 3 treatment trial sponsored by OSI Pharmaceuticals. The registry describes the study as evaluating OSI-774 (Tarceva) in patients with locally advanced, unresectable or metastatic pancreatic cancer, with gemcitabine included in the trial title.
| Feature | PA.3 |
|---|---|
| Acronym | PA.3 |
| NCT identifier | NCT00040183 |
| Phase | Phase 3 |
| Condition | Pancreatic Cancer |
| Trial status | COMPLETED |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | DOUBLE |
| Primary purpose | TREATMENT |
| Enrollment | 569 |
| Lead sponsor | OSI Pharmaceuticals |
| Sponsor type | INDUSTRY |
2. Clinical Question
The registry identifies the study population as patients with locally advanced, unresectable or metastatic pancreatic cancer and identifies OSI-774 (Tarceva, erlotinib HCl) as the registered intervention. The trial title specifies treatment with OSI-774 (Tarceva) plus gemcitabine.
Population
Patients with locally advanced, unresectable or metastatic pancreatic cancer.
Intervention
OSI-774 (Tarceva; erlotinib HCl), described in the registry as a drug intervention, with gemcitabine identified in the trial title.
Comparator
The ClinicalTrials.gov record does not identify a comparator intervention.
Primary question
The registry information establishes a randomized phase 3 treatment comparison involving OSI-774 plus gemcitabine, but does not provide a registered primary endpoint or a numerical efficacy result.
3. Trial Design
A randomized parallel-group design creates the basic statistical framework for comparing outcomes between treatment assignments. Randomization is important because, when successfully implemented, it provides the principal basis for attributing differences in outcomes between randomized groups to the assigned intervention rather than to systematic differences in patient characteristics.
Double masking adds another layer of protection against bias. In a double-masked trial, knowledge of treatment assignment is restricted according to the study's masking procedures. This can be particularly important when outcome assessment, treatment decisions, discontinuation, or reporting of adverse events could otherwise be influenced by knowledge of assignment.
4. Trial Timeline
Study start
The registry lists November 29, 2001 as the study start date.
Primary completion
The registry lists January 15, 2004 as the primary completion date.
Completed
The ClinicalTrials.gov record identifies the study status as COMPLETED.
The dates define the registry's reported study timeline. They do not, by themselves, establish the duration of individual patient follow-up, the timing of efficacy assessments, or the date of any particular statistical analysis.
5. Endpoints
That distinction matters statistically. A clinical trial can have a detailed protocol-defined statistical analysis plan even when a particular registry representation does not display registered primary endpoint information. Without a reported endpoint definition, it is not possible to identify from the registry whether the primary outcome was a time-to-event measure, a binary response measure, a continuous outcome, a safety outcome, or another endpoint.
| Endpoint field | Registry information |
|---|---|
| Registered primary endpoints | None reported |
| Endpoint definitions | Not reported in the registry information represented here |
| Endpoint time frames | Not reported in the registry information represented here |
| Posted statistical analyses | None reported |
6. Planned Analysis
The registry establishes a randomized, double-blind, parallel-group phase 3 treatment trial, but it does not report registered primary endpoints or posted statistical analyses. Consequently, the appropriate statistical approach depends on the endpoint definitions in the underlying protocol and statistical analysis plan.
For a trial in advanced cancer, a time-to-event endpoint such as overall survival would typically be summarized with Kaplan-Meier estimates and compared between randomized groups using a log-rank test, with a Cox proportional-hazards model commonly used to estimate a hazard ratio and confidence interval. A binary endpoint, such as a response proportion, would instead generally be analysed with methods appropriate for independent proportions and their confidence intervals. A continuous endpoint would generally require methods based on the distribution and structure of the measured outcome.
The choice of method is therefore not interchangeable. The statistical analysis must follow the endpoint definition, the analysis population, the censoring or missing-data rules, and the prespecified hypothesis-testing framework. The registry does not report those details here.
If a primary endpoint were time to an event, survival analysis would estimate the probability of remaining event-free beyond time t. Patients whose event has not occurred by the end of observed follow-up can contribute information through their censoring time.
7. Statistical Methodology
Randomization and causal comparison
The randomized allocation is the central design feature for an efficacy comparison. Randomization aims to balance both measured and unmeasured prognostic factors across treatment groups in expectation. That balance allows the assigned treatment groups to serve as the basis for a causal comparison, subject to departures caused by nonadherence, missing outcomes, informative censoring, protocol deviations, and other features of the actual trial conduct.
Parallel-group analysis
The parallel design means patients are allocated to treatment groups and followed within their assigned groups rather than receiving treatments in a sequence as in a crossover design. The appropriate analysis therefore ordinarily compares outcomes between independent randomized groups.
Double masking
The double-masked design is relevant to statistical validity because treatment knowledge can affect behavior and outcome assessment. Masking does not replace randomization, but it can reduce opportunities for treatment assignment to influence subsequent trial conduct.
Phase 3 inference
A phase 3 trial is generally designed to provide comparative evidence for a treatment strategy after earlier-stage investigation. Statistically, that places importance on prespecified endpoints, an explicit estimand, an analysis population, a hypothesis-testing framework, and control of type I error. The registry information represented here does not report those statistical details for PA.3.
The exact null and alternative hypotheses depend on the endpoint and effect measure. For a survival endpoint, the null might concern a hazard ratio of 1; for a binary endpoint, it might concern equality of response probabilities. The registry does not specify which framework was used for PA.3.
8. Statistical Methods Explained
Why does randomization matter statistically?
Randomization separates treatment assignment from baseline prognostic factors in expectation. This means that, before outcomes are observed, the treatment groups are generated by the allocation mechanism rather than by investigator or patient selection. It is the foundation for comparing outcomes causally between the assigned groups.
What does a parallel-group design imply for analysis?
In a parallel trial, each patient's outcome is associated with the treatment group to which that patient was randomized. The primary comparison therefore generally uses methods for independent treatment groups. Unlike a crossover design, the analysis does not rely on within-person comparisons between treatment periods.
Why is double masking useful?
Knowledge of treatment assignment can influence treatment behavior, reporting, assessment, and decisions made during follow-up. Masking reduces these potential sources of bias. It is particularly valuable when outcome assessment or patient-reported outcomes could be affected by expectations about treatment.
Why can the analysis method not be chosen from the phase alone?
Phase 3 describes the stage and general purpose of a clinical development program, not the mathematical form of its endpoint. Survival, binary, continuous, count, repeated-measures, and other endpoints require different statistical methods. The endpoint definition is therefore the starting point for selecting the analysis.
What would a hazard ratio mean if survival were the primary endpoint?
A hazard ratio would compare the estimated instantaneous event rates between randomized groups under a proportional-hazards model. A value below 1 would indicate a lower estimated event rate in the numerator group, while a value above 1 would indicate a higher estimated event rate. It would not directly represent a percentage of patients cured or an absolute difference in survival probability.
Why would a confidence interval be reported with an effect estimate?
An effect estimate alone does not show its statistical precision. A confidence interval provides an interval measure of uncertainty around the estimate under the specified model and sampling framework. Its interpretation depends on the effect measure and the assumptions underlying the analysis.
9. Analysis Populations and Estimands
The registry information identifies enrollment and the randomized design but does not provide analysis-population definitions. That omission is statistically important because different populations answer different questions.
Intention-to-treat
An intention-to-treat analysis generally compares patients according to their randomized assignment, regardless of subsequent treatment changes. This preserves the treatment-assignment comparison created by randomization.
Per-protocol
A per-protocol analysis generally focuses on patients who sufficiently followed the protocol. It can address adherence-related questions but may lose some of the protection provided by randomization.
Safety population
Safety analyses commonly use an exposure-based population, but the exact definition must be specified in the protocol or statistical analysis plan.
Estimand
The estimand defines what treatment effect is being targeted, including the population, treatment conditions, endpoint, handling of intercurrent events, and summary measure. The registry information here does not define the PA.3 estimand.
These distinctions are not merely technical. For example, discontinuation, treatment switching, rescue treatment, or other intercurrent events can change the question being answered by an analysis. A complete statistical interpretation therefore requires the prespecified handling of such events.
10. Missing Data and Censoring
The registry information does not describe missing-data rules, censoring conventions, or imputation methods for PA.3. These decisions depend on the endpoint and analysis plan.
For a time-to-event endpoint, censoring is part of the statistical design. A patient who has not experienced the event by the last relevant observation may be censored rather than treated as though the event never occurred. The validity of Kaplan-Meier and Cox analyses depends on assumptions about the censoring mechanism and the information contributed by censored observations.
For a binary or continuous endpoint, missing outcomes require different considerations. Complete-case analysis, multiple imputation, likelihood-based methods, and other approaches can produce different estimands under different assumptions. The appropriate method must therefore be specified rather than inferred from the trial phase or design alone.
11. Multiplicity and Type I Error
The registry information does not report the primary endpoint hierarchy, number of confirmatory hypotheses, alpha level, multiplicity adjustment, or interim-analysis plan for PA.3.
Multiplicity becomes important when a trial evaluates several endpoints, several treatment comparisons, multiple doses, repeated interim looks, or numerous subgroup hypotheses. Testing many hypotheses without an appropriate error-control strategy can increase the probability of at least one false-positive finding.
| Design question | What would normally be specified |
|---|---|
| Primary endpoint | The endpoint forming the principal confirmatory hypothesis |
| Significance level | The prespecified type I error threshold |
| Multiple endpoints | A hierarchy or other multiplicity-control strategy when needed |
| Interim analyses | Timing and statistical boundaries if repeated efficacy testing is planned |
| Secondary endpoints | Whether analyses are confirmatory, supportive, or exploratory |
12. Interim Analysis
The registry information does not report whether PA.3 used an interim efficacy analysis, a futility analysis, a group-sequential design, or an alpha-spending procedure.
Interim analysis can be statistically useful because accumulating information may permit a prespecified decision before the nominal final analysis. However, repeated unadjusted significance testing can increase type I error. Group-sequential and alpha-spending methods are designed to address that issue when interim looks are part of the prespecified design.
The allocation can be expressed through explicit boundaries or an alpha-spending function. The actual PA.3 approach cannot be identified from the registry information represented here.
13. Subgroup Analysis
The registry information does not provide prespecified subgroup factors or subgroup estimates for PA.3.
Subgroup analyses are generally intended to assess consistency of a treatment effect across clinically meaningful populations or to investigate potential effect modification. They are usually less precise than the overall comparison because each subgroup contains fewer patients.
A difference between two subgroup estimates is not, by itself, evidence that treatment effects differ. A formal assessment of effect modification generally requires an interaction test or another prespecified comparison of treatment effects across subgroups.
14. Safety Analysis
The registry information identifies the study as a treatment trial but does not report serious adverse-event counts by treatment arm, adverse-event rates, treatment-emergent adverse events, discontinuations because of adverse events, or other numerical safety outcomes.
| Safety measure | Registry information |
|---|---|
| Serious adverse events by arm | Not reported |
| Adverse-event counts by arm | Not reported |
| Adverse-event rates | Not reported |
| Safety analysis population | Not reported |
Safety analysis differs conceptually from efficacy analysis. Efficacy in a randomized trial is generally anchored to treatment assignment, whereas exposure-related safety questions often depend on whether and how much study treatment was actually received. The precise safety estimand and population should therefore be specified in the statistical analysis plan.
15. Results Status
The distinction between a completed trial and a trial with posted statistical analyses is important. “COMPLETED” describes the registry status of the study; it does not itself provide the numerical evidence needed to quantify a treatment effect.
16. What a Complete Statistical Result Would Contain
For an educational analysis of a randomized phase 3 treatment comparison, a complete statistical results presentation would ordinarily connect the endpoint definition to an effect measure, an uncertainty interval, and the corresponding hypothesis test.
| Component | Statistical purpose |
|---|---|
| Endpoint definition | Defines exactly what outcome is being compared |
| Analysis population | Defines which randomized or treated patients contribute to the analysis |
| Effect estimate | Quantifies the treatment contrast |
| 95% confidence interval | Describes uncertainty around the estimated effect |
| P-value | Quantifies compatibility of the observed data with a specified null hypothesis under the statistical model |
| Absolute outcome measures | Provide clinical-scale information alongside relative effects |
| Missing-data and censoring rules | Define how incomplete observations contribute to the analysis |
The absence of a numerical estimate is not equivalent to an estimate of no effect. A null result, a positive result, a negative result, and an unavailable result are four different statistical states. The registry information for PA.3 does not supply the numerical evidence required to distinguish among the first three.
17. How to Read a Future Hazard Ratio
If the primary endpoint for PA.3 were a time-to-event outcome and the analysis reported a hazard ratio, interpretation should begin with the direction of the estimate and then consider its confidence interval and analysis assumptions.
Generic hazard-ratio interpretation
A hazard ratio below 1 indicates a lower estimated instantaneous event rate in the numerator treatment group relative to the comparator group under the fitted model.
This does not mean that the same percentage of patients experience an identical reduction in individual risk. A hazard ratio is a relative time-to-event measure, not an absolute risk difference or a proportion of patients benefiting.
The confidence interval shows the precision of the estimated treatment contrast under the specified statistical model. A narrow interval indicates greater statistical precision than a wide interval, all else equal. It does not describe the range of treatment effects experienced by individual patients.
A p-value addresses compatibility of the observed data with a specified null hypothesis under the analysis model. It is not a measure of the size of the treatment effect and does not describe clinical importance.
18. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The registry establishes a randomized, double-blind, parallel-group phase 3 design with 569 enrolled patients, but it does not provide the endpoint definitions or formal statistical analyses needed to quantify an efficacy effect.
Clinical interpretation
The registry identifies the clinical population as patients with locally advanced, unresectable or metastatic pancreatic cancer and identifies OSI-774 (Tarceva) plus gemcitabine in the study title. Numerical clinical outcomes are not reported in the registry information represented here.
This distinction prevents a common analytical error: treating a trial's design characteristics as though they were evidence of an observed treatment effect. Design establishes how a comparison is intended to work; results establish what was observed.
19. Important Limitations and Interpretation Issues
- Endpoint specification: the registry information does not report registered primary endpoints, their definitions, or their time frames.
- No posted statistical analyses: the registry information does not contain formal statistical analyses or numerical primary endpoint results.
- No comparator detail: the ClinicalTrials.gov record identifies OSI-774 as the drug intervention and describes the study as randomized and parallel, but does not identify the comparator intervention.
- No analysis population definitions: the registry information does not define the intention-to-treat, per-protocol, or safety populations.
- No missing-data rules: the registry information does not describe imputation, censoring, or other missing-outcome procedures.
- No multiplicity plan: the registry information does not report endpoint hierarchy, alpha allocation, multiplicity adjustment, or interim-analysis procedures.
- No subgroup results: subgroup factors and treatment-effect estimates are not reported in the registry information represented here.
- No safety results by arm: serious adverse-event counts and other arm-specific safety results are not reported.
- Completed does not mean statistically characterized: the registry status indicates that the study is completed, but completion status alone does not provide the numerical evidence needed for an efficacy conclusion.
20. Why This Trial Matters Statistically
PA.3 provides a useful teaching example of an important distinction in clinical-trial statistics: a well-defined randomized design and a complete set of numerical results are separate components of evidence.
| Concept | How it appears in PA.3 |
|---|---|
| Randomization | The registry identifies allocation as RANDOMIZED. |
| Parallel design | The registry identifies the design model as PARALLEL. |
| Masking | The registry identifies masking as DOUBLE. |
| Phase 3 | The registry identifies the study as Phase 3. |
| Treatment purpose | The primary purpose is identified as TREATMENT. |
| Sample size | Enrollment is 569. |
| Endpoint definition | No registered primary endpoints are reported. |
| Formal statistical analysis | No posted statistical analyses are reported. |
| Safety comparison | Serious adverse events by arm are not reported. |
| Inference | Numerical treatment-effect inference cannot be obtained from the reported registry fields alone. |
For biostatisticians, this is a useful reminder that the analysis cannot be separated from the estimand. Before choosing Kaplan-Meier, Cox regression, logistic regression, ANCOVA, a mixed model, or another method, the analyst must know what outcome is being estimated and which patients and intercurrent events are part of the target question.
21. From Trial Design to Statistical Analysis
Step 1 · Define the endpoint
Specify the event, measurement, assessment window, and rules for determining whether an observation meets the endpoint definition.
Step 2 · Define the estimand
Specify the population, treatment conditions, endpoint, handling of intercurrent events, and summary measure.
Step 3 · Choose the model
Select a method appropriate for the endpoint, such as survival, binary, continuous, repeated-measures, or another framework.
Step 4 · Quantify uncertainty
Report an effect estimate together with an appropriate confidence interval and the prespecified hypothesis test where applicable.
This sequence is more reliable than selecting a statistical test first. The clinical question determines the estimand; the estimand and endpoint determine the appropriate analysis; and the analysis produces the effect estimate and uncertainty measures used for interpretation.
22. A Statistical Checklist for PA.3
| Question | Registry status |
|---|---|
| Was the trial randomized? | Yes — RANDOMIZED |
| Was the design parallel? | Yes — PARALLEL |
| Was masking reported? | Yes — DOUBLE |
| Was the primary purpose treatment? | Yes — TREATMENT |
| Was the study phase reported? | Yes — Phase 3 |
| Was enrollment reported? | Yes — 569 |
| Were registered primary endpoints reported? | No |
| Were endpoint definitions reported? | No |
| Were formal statistical analyses posted? | No |
| Were primary efficacy estimates reported? | No |
| Were confidence intervals reported? | No |
| Were p-values reported? | No |
| Were serious adverse events reported by arm? | No |
23. Sources
- ClinicalTrials.gov: NCT00040183 — PA.3.
Continue through the Clinical Biostats clinical-trial library
Explore additional clinical-trial analyses and statistical methods across randomized clinical research.
24. Record Summary
PA.3 is registered as a completed randomized, double-blind, parallel-group phase 3 treatment trial sponsored by OSI Pharmaceuticals. The registry identifies pancreatic cancer as the condition, 569 as the enrollment, OSI-774 (Tarceva; erlotinib HCl) as the drug intervention, and November 29, 2001 and January 15, 2004 as the study start and primary completion dates, respectively.
From a statistical perspective, the most important feature of the available registry information is the distinction between trial design and reported statistical evidence. The design provides a randomized framework for comparative inference, but the registry information does not report registered primary endpoints, endpoint definitions, analysis populations, formal statistical methods, numerical efficacy estimates, confidence intervals, p-values, or arm-specific serious adverse-event results.